Abstract
The article analyzes the problem of placing medicinal products on the market and the faulty implementation of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. As a result of faulty implementation, manufacturers of medicinal products have been deprived of the possibility to market the medicines they produce. This results in significant losses and distortion of competition in the pharmaceutical market. The article offers proposals of specific legislative changes and legal measures available for manufacturers of medicinal products. In addition, the issue of marketing of dietary supplements is addressed. They are advertised as if they were medicines thereby misleading the consumers. The article describes the risks associated with this problem and suggests proposals of change.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
